Nuevos productosSalud - Farma - Biotecnología
Inside Information / Other news releases
18/11/2026 08:30
AMFPublicación inmediata
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced initial Phase 1 data from its ongoing study of IPH4502, an investigational Nectin- 4-targeting antibody-drug conjugate (ADC) incorporating an exatecan payload, in patients with advanced solid tumors.…
INNATE PHARMA PRESENTS INITIAL PHASE 1 CLINICAL DATA FOR
IPH4502 AT ENA 2026
- Encouraging tolerability profile with stomatitis as the only dose-limiting toxicity; low overall hematologic toxicity, consistent with low circulating free-exatecan levels, supporting linker stability
- Antitumor activity observed across tumor types, including in post-enfortumab vedotin urothelial cancer; ORR of 33% (2/6) at the maximum tolerated dose of 3.6 mg/kg Q3W in non-urothelial tumors
- Initiating dose optimization with first patient planned in H1 2027, to further characterize safety and activity in post-EV urothelial cancer at upper dose levels and define a recommended Phase 2 dose and schedule
- Following the poster presentation at ENA (poster), Innate will host an in-person and virtual key opinion leader (KOL) event focused on IPH4502, today at 11:00 a.m. ET / 4:00 p.m. GMT (webcast link)
Marseille, France, November 18, 2026, 8:30 AM CET
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced initial Phase 1 data from its ongoing study of IPH4502, an investigational Nectin- 4-targeting antibody-drug conjugate (ADC) incorporating an exatecan payload, in patients with advanced solid tumors. The results are being presented today at the 38th EORTC-NCI- AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026).
“The Phase 1 findings provide an encouraging foundation for the continued development of IPH4502,” said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. “The observed antitumor activity and safety profile strengthen our commitment to advancing this program, particularly for patients with urothelial cancer previously treated with enfortumab vedotin, where significant unmet need remains. Our focus now is on optimizing the dose and schedule to further characterize antitumor activity and tolerability in this setting and inform selection of a recommended Phase 2 regimen.”
Study Population and Background
The Phase 1 dose-escalation study of IPH4502 enrolled 76 patients with advanced solid tumors across six dose levels ranging from 0.6 mg/kg to 3.6 mg/kg, administered once every three weeks. Patients were heavily pretreated, with a median of 3.5 prior lines of systemic therapy and represented more than 10 tumor types. Nineteen patients had urothelial cancer (UC), all of whom had previously received PADCEV® (enfortumab vedotin). The primary objective of the study was to assess the safety and tolerability of IPH4502, while secondary objectives include evaluating its pharmacokinetics and antitumor activity in patients with advanced solid tumors.
Safety and Tolerability
As of the August 17, 2026 data cutoff, IPH4502 was well-tolerated during Phase 1 dose escalation, with low overall hematologic toxicity.